Neuronostics

Neuronostics is a medical technology company spun out of the University of Exeter in 2018, specializing in the diagnosis and monitoring of neurological conditions. The company was co-founded by Professor John Terry and Dr. Wessel Woldman, who leveraged their research into mathematical modeling of biomedical systems. Their work began in 2012, focusing on the mathematical analysis of EEG signals, which led to the methodology behind their core product. Professor Terry is also the Director of the Centre for Systems Modelling & Quantitative Biomedicine at the University of Birmingham, and Dr. Woldman has held prestigious fellowships from Epilepsy Research UK and the Medical Research Council.

The company's core technology is BioEP, a patented digital biomarker that analyzes routinely collected electroencephalogram (EEG) recordings to produce a seizure risk score. This system applies mathematical models and AI to short segments of EEG data to identify features and brain network markers that are often hidden from standard clinical observation. The technology aims to significantly reduce the time and cost associated with diagnosing epilepsy, as approximately 70% of initial EEGs are inconclusive. BioEP provides clinicians with an additional layer of objective evidence to support their diagnostic and treatment decisions, even when traditional epileptiform rhythms are absent in the EEG data.

Neuronostics operates on a software-as-a-medical-device (SaaMD) business model, providing its technology through a scalable, cloud-based platform to neurology centers, hospitals, and clinical research organizations. The company generates revenue by offering its neuro-seizure assessment software to clinicians. It has formed strategic partnerships with companies like Neuroelectrics to provide integrated EEG solutions for clinical trials, enhancing cohort identification and data analysis for pharmaceutical companies and academic partners. The company has received significant funding, including a £2.1 million seed round in April 2024 led by the Ascension Life Fund, and grants from Innovate UK and the National Institute for Health Research (NIHR). This funding supports its market expansion in the UK and Middle East, as well as efforts to secure FDA regulatory approval for the US market.

Keywords: epilepsy diagnosis, digital biomarkers, EEG analysis, neurological conditions, mathematical modeling, seizure risk score, MedTech, neurotechnology, clinical decision support, brain modeling, quantitative biomedicine, BioEP, computational neurology, AI in healthcare, prognostic tools, patient monitoring, anti-epileptic drugs, clinical trials, diagnostic software, health technology